Migraine
📧 Sign up to get email alerts when something new happens for Migraine.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-08-12FDA Approved: DIVALPROEX SODIUM — Original Application (First Nation Group, LLC)
FDA approved the original ANDA for divalproex sodium from First Nation Group, LLC, authorizing a generic product to be marketed for the same…
-
FDA approval · 2025-08-05FDA Approved: AJOVY — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for AJOVY (fremanezumab-vfrm) from Teva, updating its labeling to reflect the approved supplemental …
-
FDA approval · 2025-08-01FDA Approved: NURTEC ODT — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved Pfizer's supplemental application for Nurtec ODT (rimegepant sulfate). The approval updates/expands the product's labeling …
-
FDA approval · 2025-08-01FDA Approved: ZAVZPRET — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approves a supplemental application for Zavzpret (zavegepant) submitted by Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2025-07-25FDA Approved: SUMATRIPTAN — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for Sumatriptan from Eugia US LLC under ANDA 202758.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-07-23FDA Approved: TOPIRAMATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Topiramate from Aurobindo Pharma Limited under an existing ANDA.
-
FDA approval · 2025-07-07FDA Approved: ELETRIPTAN HYDROBROMIDE — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' Eletriptan Hydrobromide as an original generic application for the acute treatment of migraine in a…
-
FDA approval · 2025-06-24FDA Approved: AMITRIPTYLINE HYDROCHLORIDE — Supplemental Application (Advagen Pharma Ltd)
The FDA approved a supplemental application for amitriptyline hydrochloride by Advagen Pharma Ltd, indicating an approved change to an alrea…
-
FDA approval · 2025-06-24FDA Approved: AMITRIPTYLINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Amitriptyline Hydrochloride from Aurobindo Pharma Limited, authorizing a generic product's appro…
-
FDA approval · 2025-06-10FDA Approved: QULIPTA — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for QULIPTA (atogepant) submitted by AbbVie Inc.
-
FDA approval · 2025-06-05FDA Approved: UBRELVY — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for UBRELVY (ubrogepant) by Allergan, Inc.
-
FDA approval · 2025-05-27FDA Approved: TOPIRAMATE — Original Application (Advagen Pharma Ltd)
FDA approved the original ANDA for Topiramate by Advagen Pharma Ltd, providing a generic version of the anticonvulsant. The drug is indicate…
-
FDA approval · 2025-05-14FDA Approved: BREKIYA — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Brekiya (dihydroergotamine mesylate) from Amneal Pharmaceuticals in an original application for the acute treatment of migraine…
-
FDA approval · 2025-05-09FDA Approved: ASCOMP WITH CODEINE — Supplemental Application (LGM PHARMA SOLUTIONS, LLC)
The FDA approved a supplemental application for ASCOMP WITH CODEINE, a combination product of butalbital, aspirin, caffeine, and codeine pho…
-
FDA approval · 2025-04-30FDA Approved: ATZUMI — Original Application (Satsuma Pharmaceuticals, Inc.)
FDA approved ATZUMI (dihydroergotamine mesylate) from Satsuma Pharmaceuticals in NDA217901 for the acute treatment of migraine.
-
FDA approval · 2025-04-15FDA Approved: ALMOTRIPTAN MALATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application to allow the sale of almotriptan malate (almotriptan) as a generic product by Mylan for acute tr…
-
FDA approval · 2025-04-15FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for divalproex sodium.
-
EMA approval · 2025-04-04EMA Authorised: Ajovy (fremanezumab) — Teva GmbH
The European Medicines Agency authorised Ajovy (fremanezumab) by Teva GmbH for migraine disorders, marking EU marketing authorization for th…
-
FDA approval · 2025-03-28FDA Approved: SUMATRIPTAN — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for Sumatriptan submitted by Rising Pharma Holdings, Inc.
-
FDA approval · 2025-03-27FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for divalproex sodium (divalproex) by Aurobindo Pharma Limited. The approval pertains to the generic…
-
FDA approval · 2025-03-26FDA Approved: RIZATRIPTAN BENZOATE — Supplemental Application (Panacea Biotec Limited)
FDA approved a supplemental application for Rizatriptan Benzoate by Panacea Biotec Limited. The approval makes a generic rizatriptan benzoat…
-
FDA approval · 2025-03-21FDA Approved: NURTEC ODT — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA supplemental application for Nurtec ODT (rimegepant sulfate) submitted by Pfizer Laboratories Div Pfizer Inc to modify labeling and/or e…
-
FDA approval · 2025-03-21FDA Approved: AJOVY — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for AJOVY (fremanezumab-vfrm) from Teva Pharmaceuticals USA, Inc., resulting in an approved upda…
-
FDA approval · 2025-03-21FDA Approved: VYEPTI — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved a supplemental application for VYEPTI (eptinezumab-jjmr) from Lundbeck Pharmaceuticals LLC.
-
FDA approval · 2025-03-21FDA Approved: ZAVZPRET — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for ZAVZPRET (zavegepant) submitted by Pfizer Laboratories Div Pfizer Inc.